Trials / Terminated
TerminatedNCT00086606
A Safety and Efficacy Study of Xolair in Peanut Allergy
A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xolair (omalizumab) |
Timeline
- Start date
- 2004-06-01
- Completion
- 2006-04-01
- First posted
- 2004-07-09
- Last updated
- 2013-01-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00086606. Inclusion in this directory is not an endorsement.